30
/it/
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
April 1, 2024
2135693
178559
2

28 sett 2017 anni - FDA sent letters to IR opioid analgesic manufacturers informing them that their products that are intended to be used in the outpatient setting will be subject to the same REMS requirements as the ER/LA opioid analgesics.

Aggiunto al nastro di tempo:

13 nov 2018

Data:

28 sett 2017 anni
Adesso
~ 6 years and 8 months ago